In addition, a phase II clinical study showed that MMP7 protein levels decreased in a dose-dependent manner after using JNK inhibitors, indicating that the use of MMP7 to track IPF progression has potential clinical benefits (van der Velden et al., 2016). Here, MMP7 is linked to idiopathic pulmonary fibrosis.